0.28p
-3.51%
Close of 9 Nov 2026, in pence
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Aptamer Group
Its shares trade on LSE under the ticker APTA.L. It has been listed since 22 December 2021. In the fiscal year to 30 June 2026, it reported revenue of £1.5m and a net loss of £1.9m. At that date it held total assets of £7.2m and shareholders' equity of £5.7m.
Aptamer Group Plc is a biotechnology company, which engages in the development of Optimer binders for use in research, diagnostics, and therapeutics. The company is headquartered in York, North Yorkshire. The company went IPO on 2021-12-22. The company offers custom Optimer selection and development services. The company delivers aptamer-based solutions to its customer bases for a range of therapeutic, diagnostic, and target-binding applications. The company develops Optimer binders for therapeutics, diagnostics, bioprocessing, and research applications. The Optimer platform delivers aptamer tools that enables researchers and developers across the spectrum of the life sciences. Optimer binders has developed for a range of applications, including therapeutic inhibitors and modulators, drug delivery vehicles, protein purification and separation, biomarker screening and validation, in vitro research, quality control analysis, pharmacokinetic and drug assays, and in vitro diagnostic assays. Optimer act as agonists, antagonists, or cell-type-specific targeting moieties for the delivery of therapeutic agents to target cells and tissues in the treatment of disease.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Biotechnology
- Listed since
- 22 Dec 2021
- Employees
- 44
- Website
- aptamergroup.co.uk ↗
Leadership
Pay as last reported
- Arron Tolley, PhDChief Executive Officer & Director, since 2008
- Eleanor Courtman-StockChief Financial Officer & Secretary, since 2018
- David Bunka, PhDDirector & Chief Technology Officer, since 2008
- Ilknur DereliAssociate Director-Business Development, since 2022
- Derek SmithDirector-Global Sales, since 2018
- Ian David Gilham, PhDNon-Executive Chairman
- Arron Tolley, PhDChief Executive Officer & Director, since 2008
- David Bunka, PhDDirector & Chief Technology Officer, since 2008
- Angela HildrethNon-Executive Director
- John D. Richards, PhDNon-Executive Director
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Aptamer Group PLC develops Optimer binders for research applications in the Health Care sector.
- The company offers custom Optimer selection services to customers in the biotechnology industry.
- Optimer binders act as agonists for the delivery of therapeutic agents to target cells.
Weaknesses
- The company has only 44 employees, which limits its operational capacity significantly.
- Aptamer Group PLC is headquartered in York, North Yorkshire, a smaller regional market.
- The company went IPO on 22 December 2021, indicating a relatively recent market presence.
Opportunities
- The company delivers aptamer-based solutions for diagnostic applications to expand its customer base.
- Optimer tools enable researchers across the life sciences spectrum to utilize advanced binders.
- The platform supports protein purification and separation for bioprocessing applications in the market.
Threats
- Competition exists for therapeutic inhibitors and modulators within the biotechnology industry sector.
- Quality control analysis requires rigorous standards that may challenge the small employee base.
- In vitro diagnostic assays face regulatory scrutiny in the Health Care sector globally.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.